Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis.

ABSTRACT:

Aims

The aim of this study was to continually evaluate the association between cardiovascular drug exposure and COVID-19 clinical outcomes (susceptibility to infection, disease severity, hospitalization, hospitalization length, and all-cause mortality) in patients at risk of/with confirmed COVID-19.

Methods

Eligible publications were identified from more than 500 databases on 1 November 2020. One reviewer extracted data with 20% of the records independently extracted/evaluated by a second reviewer.

Results

Of 52 735 screened records, 429 and 390 studies were included in the qualitative and quantitative syntheses, respectively. The most-reported drugs were angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) with ACEI/ARB exposure havin

SUBMITTER: Asiimwe IG 

PROVIDER: S-EPMC8239929 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature